Photo: JACK GUEZ / AFP / Getty Images
The American pharmaceutical company Pfizer disclosed this Wednesday that a third dose of its vaccine against COVID- 19 can “push hard” protection against Delta variant of the coronavirus against a two-dose regimen, according to preliminary data from a study.
The company indicated in a presentation that its data suggests that a third dose produces antibody levels against the Delta variant five times higher in people between 18 Y 55 years, and more than 11 times in people between 65 and 85 years , compared to levels after the second dose.
Pfizer calculates that that third dose could potentially multiply by 100 the neutralization of the delta variant compared to a two-dose regimen, according to the document, which was used by the company in a conference call to discuss its quarterly financial results.
As explained by executives at the conference, Pfizer believes “likely that a third booster dose will be needed between 6 and 12 months after complete vaccination to maintain high levels of protection ”against covid – 19, and they thought that the delta variant is “the most transmissible” seen so far.
The study, which is in progress and has not been subjected to peer review, also seems to indicate that a third dose given at least half a year after the second is well tolerated and generates high levels of antibodies against coronavir us original and beta variant.
Pfizer said earlier this month that it intended apply for authorization from the US Food and Drug Administration (FDA) to provide a third dose of the covid vaccine , which it has developed together with the German company BioNTech.
“The companies hope to publish more definitive data on the analysis and all the accumulated data will be shared as part of the current discussions with the FDA, the EMA (European Medicines Agency) and other regulators in the coming weeks, ”the pharmaceutical company noted in a note.
With information from Efe.
Continue Reading: Joe Biden warns that cyberattacks could trigger a “real armed conflict”